 Shares of Momenta Pharmaceuticals NASDAQ: MNTA soared on Wednesday after the biotechnology company announced it had agreed to be acquired by Johnson Johnson NYSE: JNJ. As of 1:40 p.m. EDT, Momentas stock was up 69. In return, JJ would receive full global rights to Momentas experimental antibody, nipocalimab, which could potentially be used to treat a number of autoimmune diseases. 